Genetic association of single nucleotide polymorphisms in P53 pathway with gastric cancer risk in a Chinese Han population

Medical Oncology

Volumn 32, Issue 1, 2015, Pages 1-5

  Wu, Guo Cong ^a   Zhang, Zhong Tao ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Chinese Han; Gastric cancer; P53 pathway; Polymorphism

Indexed keywords

DEUBIQUITINASE; HERPES VIRUS ASSOCIATED UBIQUITIN SPECIFIC PROTEASE; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; UNCLASSIFIED DRUG; MDM2 PROTEIN, HUMAN; MDM4 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; TP53 PROTEIN, HUMAN; UBIQUITIN THIOLESTERASE; USP7 PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER RISK; CONTROLLED STUDY; DRINKING BEHAVIOR; FEMALE; GENE INTERACTION; GENETIC ASSOCIATION; GENOTYPE; HAN CHINESE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; STOMACH CANCER; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; ODDS RATIO; POLYMERASE CHAIN REACTION; STOMACH TUMOR;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; STOMACH NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN THIOLESTERASE;

EID: 84920111679     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0401-1     Document Type: Article

References (34)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.
2. Crew KD, Neugut AI. Epidemiology of upper gastrointestinal malignancies. Semin Oncol. 2004;31(4):450–64.
3. Shi Y, Hu Z, Wu C, Dai J, Li H, Dong J, Wang M, Miao X, Zhou Y, Lu F, et al. A genome-wide association study identifies new susceptibility loci for non-cardia gastric cancer at 3q13.31 and 5p13.1. Nat Genet. 2011;43(12):1215–8.
4. Saeki N, Ono H, Sakamoto H, Yoshida T. Genetic factors related to gastric cancer susceptibility identified using a genome-wide association study. Cancer Sci. 2013;104(1):1–8.
5. Moll UM, Petrenko O. The MDM2-p53 interaction. Mol Cancer Res. 2003;1(14):1001–8.
6. Wu H, Leng RP. UBE4B, a ubiquitin chain assembly factor, is required for MDM2-mediated p53 polyubiquitination and degradation. Cell Cycle. 2011;10(12):1912–5.
7. Poyurovsky MV, Katz C, Laptenko O, Beckerman R, Lokshin M, Ahn J, Byeon IJ, Gabizon R, Mattia M, Zupnick A, et al. The C terminus of p53 binds the N-terminal domain of MDM2. Nat Struct Mol Biol. 2010;17(8):982–9.
8. Toledo F, Wahl GM. MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol. 2007;39(7–8):1476–82.
9. Brooks CL, Li M, Hu M, Shi Y, Gu W. The p53–Mdm2–HAUSP complex is involved in p53 stabilization by HAUSP. Oncogene. 2007;26(51):7262–6.
10. Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer. 2006;6(12):909–23.
11. Assmann G, Wieczorek S, Wibisono D, Roemer K, Arning L, Voswinkel J. The p53 G72C and MDM2 T309G single nucleotide polymorphisms in patients with Wegener’s granulomatosis. Clin Exp Rheumatol. 2008;26(3 Suppl 49):S72–5.
12. Chen T, Yi SH, Liu XY, Liu ZG. Meta-analysis of associations between the MDM2-T309G polymorphism and prostate cancer risk. Asian Pac J Cancer Prev. 2012;13(9):4327–30.
13. Ebid GT, Sedhom IA, El-Gammal MM, Moneer MM. MDM2 T309G has a synergistic effect with P21 ser31arg single nucleotide polymorphisms on the risk of acute myeloid leukemia. Asian Pac J C Prev. 2012;13(9):4315–20.
14. Faur N, Araud L, Laroche-Clary A, Kanno J, Toutain J, Yamori T, Robert J, Le Morvan V. The association between the T309G polymorphism of the MDM2 gene and sensitivity to anticancer drug is dependent on the p53 mutational status in cellular models. Br J Cancer. 2009;101(2):350–6.
15. Liu G, Cescon DW, Zhai R, Zhou W, Kulke MH, Ma C, Xu W, Su L, Asomaning K, Heist RS, et al. p53 Arg72Pro, MDM2 T309G and CCND1 G870A polymorphisms are not associated with susceptibility to esophageal adenocarcinoma. Dis Esophagus. 2010;23(1):36–9.
16. Onat OE, Tez M, Ozcelik T, Toruner GA. MDM2 T309G polymorphism is associated with bladder cancer. Anticancer Res. 2006;26(5A):3473–5.
17. Pastor-Idoate S, Rodriguez-Hernandez I, Rojas J, Fernandez I, Garcia-Gutierrez MT, Ruiz-Moreno JM, Rocha-Sousa A, Ramkissoon Y, Harsum S, MacLaren RE, et al. The T309G MDM2 gene polymorphism is a novel risk factor for proliferative vitreoretinopathy. PLoS One. 2013;8(12):e82283.
18. Song B, Duan ZY, Zhong YH, Lei N, Yang YQ, Luo KY. Meta-analysis of the MDM2 T309G polymorphism and gastric cancer risk. Asian Pac J Cancer Prev. 2013;14(11):6649–51.
19. Yang M, Guo Y, Zhang X, Miao X, Tan W, Sun T, Zhao D, Yu D, Liu J, Lin D. Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis. 2007;28(9):1996–2001.
20. Levine AJ, Hu W, Feng Z. The P53 pathway: what questions remain to be explored? Cell Death Differ. 2006;13(6):1027–36.
21. Bennett WP, Hussain SP, Vahakangas KH, Khan MA, Shields PG, Harris CC. Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer. J Pathol. 1999;187(1):8–18.
22. Stoll C, Baretton G, Lohrs U. The influence of p53 and associated factors on the outcome of patients with oral squamous cell carcinoma. Virchows Arch. 1998;433(5):427–33.
23. Wo X, Han D, Sun H, Liu Y, Meng X, Bai J, Chen F, Yu Y, Jin Y, Fu S. MDM2 SNP309 contributes to tumor susceptibility: a meta-analysis. J Genet Genom. 2011;38(8):341–50.
24. Moradi MT, Salehi Z, Asl SF, Aminian K, Hashtchin AR. Helicobacter pylori infection and MDM2 SNP309 association with gastric cancer susceptibility. Genet Test Mol Biomarkers. 2013;17(11):794–8.
25. Chen T, Yi SH, Liu XY, Liu ZG. Meta-analysis of associations between the MDM2-T309G polymorphism and prostate cancer risk. Asian Pac J Cancer Prev. 2012;13(9):4327–30.
26. Liu J, Zheng YY, Lei DP, Liu DY, Xu FL, Jin T, Cao XL, Zhao XN, Yu XM, Pan XL. MDM2 309T> G polymorphism and risk of squamous cell carcinomas of head and neck: a meta-analysis. Asian Pac J Cancer Prev. 2011;12(8):1899–903.
27. Ma HB, Huang T, Han F, Chen WY. Association between MDM2 promoter SNP309 T/G polymorphism and liver cancer risk—a meta-analysis. Asian Pac J Cancer Prev. 2012;13(6):2841–6.
28. Ren YW, Yin ZH, Wan Y, Guan P, Wu W, Li XL, Zhou BS. P53 Arg72Pro and MDM2 SNP309 polymorphisms cooperate to increase lung adenocarcinoma risk in Chinese female non-smokers: a case control study. Asian Pac J Cancer Prev. 2013;14(9):5415–20.
29. Tian X, Tian Y, Ma P, Sui CG, Meng FD, Li Y, Fu LY, Jiang T, Wang Y, Ji FJ, et al. Association between MDM2 SNP309T> G and risk of gastric cancer: a meta-analysis. Asian Pac J Cancer Prev. 2013;14(3):1925–9.
30. Kang HJ, Feng Z, Sun Y, Atwal G, Murphy ME, Rebbeck TR, Rosenwaks Z, Levine AJ, Hu W. Single-nucleotide polymorphisms in the p53 pathway regulate fertility in humans. Proc Natl Acad Sci USA. 2009;106(24):9761–6.
31. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119(5):591–602.
32. Ohmiya N, Taguchi A, Mabuchi N, Itoh A, Hirooka Y, Niwa Y, Goto H. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol. 2006;24(27):4434–40.
33. Ma Y, Bian J, Cao H. MDM2 SNP309 rs2279744 polymorphism and gastric cancer risk: a meta-analysis. PLoS One. 2013;8(2):e56918.
34. Su XL, Jin JJ. Pro variant of TP53 Arg72Pro contributes to gastric cancer risk in Asians: evidence from a meta-analysis. Asian Pac J Cancer Prev. 2012;13(3):915–21.